CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

IAS 2023

the 12th IAS Conference on HIV Science

July 23-26, 2023
Brisbane, Australia & Virtual

  • Cabotegravir Treatment

    Elliot E, et al.

    Similar inflammatory markers after switching to cabotegravir + rilpivirine long-acting vs. continuing bictegravir/emtricitabine/tenofovir alafenamide: data from the phase 3b SOLAR trial.

    View Poster

    Eu B, et al.

    Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and body mass index: a subgroup analysis of the phase 3b SOLAR study.

    View Poster

    Gutner CA, et al.

    Optimizing the clinic flow process for integration of cabotegravir + rilpivirine long acting into routine care: findings from cabotegravir and rilpivirine implementation study in European locations (CARISEL).

    View Poster

    Scherzer J, et al.

    Perceptions of cabotegravir + rilpivirine long-acting (CAB+RPV LA) from people living with HIV (PLHIV) in the CARLOS study.

    View Poster

    Chounta V, et al.

    Patient-reported outcomes after 12 months of maintenance therapy with long acting cabotegravir and rilpivirine compared with bictegravir emtricitabine tenofovir alafenamide in the phase 3b SOLAR study.

    View Poster

  • Dolutegravir-based Regimens

    Patel P, et al.

    Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks.

    View Poster

    Puthanakit T, et al.

    Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in antiretroviral therapy (ART)-naive adolescents living with HIV-1: DANCE study Week 96 results.

    View Poster

    Smith DE, et al.

    Switching to dolutegravir/lamivudine (DTG/3TC) is non-inferior to continuing tenofovir alafenamide (TAF)-based regimens at Week 196: TANGO subgroup analyses.

    View Poster

    Mussini C, et al.

    Real-world observational study in Europe on the effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor (COMBINE-2): Week 96 stable switch population results.

    View Poster

    Rupasinghe D, et al.

    Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes.

    View Poster

    Byonanebye DM, et al.

    Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia in RESPOND.

    View Poster

  • Cabotegravir Prevention

    Poteat R, et al.

    Risk characteristics, risk perception, and long-acting PrEP awareness and interest among black and Hispanic men: a national survey.

    View Poster

    Elion RA, et al.

    Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine in the United States: TRIO cohort study.

    View Poster

  • Disease-Related Content

    Choi JY, et al.

    Development of the HIV Care Continuum & Beyond Initiative: key focus areas to end HIV in the Asia-Pacific region.

    View Poster

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.